Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2023-12, Vol.142 (26), p.2327-2331
Hauptverfasser:	Qualls, David A., Lambert, Nicholas, Caimi, Paolo F., Merrill, Mwanasha, Pullarkat, Priyanka, Godby, Richard C., Bond, David A., Wehmeyer, Graham T., Romancik, Jason, Amoozgar, Behzad, Leslie, Lori, Nastoupil, Loretta J., Crombie, Jennifer L., Abramson, Jeremy S., Khurana, Arushi, Nowakowski, Grzegorz S., Maddocks, Kami, Rutherford, Sarah C., Kahl, Brad, Okwali, Michelle, Buege, Michael J., Seshan, Venkatraman, Batlevi, Connie L., Salles, Gilles
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Humans Lenalidomide - therapeutic use Letter to Blood Lymphoma, Large B-Cell, Diffuse - drug therapy Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.
ISSN:	0006-4971 1528-0020 1528-0020
DOI:	10.1182/blood.2023021274